IGFBP2 and cancer: Our data indicated that estrogen-mediated inhibition of p53 in H1299L858R cancer cells changed the protein composition (FGF2, GDF15, IGFBP2, CCL5, PTX3, VEGF, and MMP9) of conditioned medium.